RedHill Biopharma Moves to Advance Opaganib as Oral Antiviral Option for Current Ebola Outbreak

RedHill Biopharma has announced it is seeking collaborations to advance the clinical development of opaganib, an oral investigational drug designed to combat Ebola virus disease. The company is specifically focusing on the current outbreak of the rare Bundibugyo ebolavirus subtype.

Strategic Partnerships and Global Response

The company is currently engaged in discussions regarding potential partnerships with pharmaceutical firms. These talks include possible participation in the World Health Organization’s SOLIDARITY CORE platform.

To accelerate regulatory and trial discussions, RedHill has shared existing supply along with clinical and preclinical data with relevant authorities. This move aims to streamline the process of bringing the treatment to those in need.

Did You Know? Opaganib is an investigational SPHK2 inhibitor being developed not only for viral threats but also for multiple oncology, inflammatory, and metabolic indications.

The Science Behind Opaganib

Opaganib utilizes a dual rationale, acting as both a host-directed and direct-acting antiviral. This approach is supported by Phase 3 data from severe COVID-19 cases, which demonstrated faster viral clearance and reduced mortality.

preclinical studies funded by USAMRIID have indicated that the drug inhibits Ebola and provides survival benefits in animal models. These studies also highlighted a synergy when used alongside remdesivir.

Expert Insight: Samantha Carter notes that the shift toward oral formulations is critical for biodefense. The ease of storage and administration associated with an oral drug could significantly lower the logistical barriers typically found in emergency outbreak responses.

Implications for Global Biodefense

Due to its apparent safety profile and ease of storage, RedHill is positioning opaganib as a candidate for broader biodefense stockpiling. The goal is to strengthen global infectious disease preparedness by complementing existing direct-acting antivirals.

Looking forward, the drug may undergo further trials if collaborations with the WHO or other pharma partners are finalized. Regulatory approvals could potentially depend on the outcome of these ongoing discussions and the application of existing preclinical data.

Company Overview and Market Standing

Based in Raleigh and Tel Aviv, RedHill Biopharma specializes in oral, small-molecule therapies. While the company focuses on infectious diseases and oncology, its financial position remains complex.

RedHill Biopharma reveal promising results from Covid-19 candidate Opaganib

According to Spark, an AI Analyst from TipRanks, the stock (RDHL) is rated as Neutral. This is attributed to sustained cash burn, operating losses, and a sharp decline in revenue, despite achieving positive equity and lower debt in 2025.

The company currently holds a market capitalization of $5.19M, with an average trading volume of 56,273. Technical sentiment for the stock is currently listed as a Sell.

To see Spark’s full report on RDHL stock, click here.

Frequently Asked Questions

What is opaganib and how is it administered?

Opaganib is an investigational SPHK2 inhibitor that functions as a dual host-directed and direct-acting antiviral. It is developed as an oral formulation, which allows for easier administration and storage.

Which specific virus is RedHill Biopharma targeting currently?

The company is pursuing the development of opaganib against Ebola virus disease, with a particular focus on the rare Bundibugyo ebolavirus subtype.

What evidence exists for the drug’s efficacy?

The company cites Phase 3 data in severe COVID-19 showing reduced mortality and faster viral clearance, as well as USAMRIID-funded preclinical studies showing Ebola inhibition and survival benefits in animals.

How might the availability of oral antiviral treatments change the way global health organizations respond to rare viral outbreaks?